Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy.

Abstract

Although the highly permeable membranes utilized in hemofiltration are theoretically more permeable to deferoxamine-chelated iron than the standard cuprophan membranes used in conventional hemodialysis, no clinical data support this contention. Ours are the first published results of a preliminary short-term trial of combined therapy with deferoxamine and hemofiltration in a dialysis patient with hemosiderosis. An average of 15.3 mg of iron was mobilized with a 19.5-liter exchange over only 4 1/2 hours of postdilution hemofiltration. This compares favorable with previous reports in which 8 to 12 hours of dialysis were performed with Kiil dialyzers, and also with the 24-hour urinary excretion of chelated iron in iron-overloaded patients with normal renal function. We conclude that combined therapy with deferoxamine and hemofiltration offers promises as an effective means of iron mobilization in dialysis patients with hemosiderosis.

• Authors: J T McCarthy, C R Libertin, J C Mitchell 3rd, V F Fairbanks
• Journal: Mayo Clinic proceedings (Mayo Clin Proc) Vol. 57 Issue 7 Pg. 439-41 (Jul 1982) ISSN: 0025-6196 [Print] England
• PMID: 7087549 (Publication Type: Case Reports, Journal Article)

Chemical References

• Drug Combinations
• Deferoxamine

Topics

• Aged
• Blood
• Deferoxamine (therapeutic use)
• Drug Combinations
• Female
• Hemosiderosis (etiology, therapy)
• Humans
• Nephrosclerosis (complications, therapy)
• Renal Dialysis
• Ultrafiltration (methods)